Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus
Published . Updated .
Key takeaways
- Conference spotlight on Vertex Pharmaceuticals and a busy late stage pipeline Vertex Pharmaceuticals (VRTX) heads into back to back London conference appearances as investors watch for commentary on a November 30 U.S.
- Exposed: XLV, XBI, JNJ, VRTX, PFE
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest and never sell or share it. See our privacy policy.
Conference spotlight on Vertex Pharmaceuticals and a busy late stage pipeline Vertex Pharmaceuticals (VRTX) heads into back to back London conference appearances as investors watch for commentary on a November 30 U.S. regulatory decision for kidney drug povetacicept and a
Directly affected
- VRTX Vertex Pharmaceuticals Inc / Ma+3.8% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- EWU iShares MSCI United Kingdom ETF+0.6% 10d
iShares MSCI United Kingdom ETF holds stocks listed in the UK, which this story is about (“london”).
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| VRTX | +2.45% | +0.84% | base | after close | after close | after close | after close |
| XLV | +2.00% | +1.95% | base | after close | after close | after close | after close |
| XBI | +7.54% | +3.62% | base | after close | after close | after close | after close |
| EWUNo price data for this ticker | — | — | — | — | — | — | — |
| LLY | +1.56% | +2.06% | base | after close | after close | after close | after close |
| JNJ | +0.58% | +2.60% | base | after close | after close | after close | after close |
| PFE | +3.48% | +1.55% | base | after close | after close | after close | after close |
| MRK | +2.66% | +3.05% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus Yahoo Finance
Source: Yahoo Finance
Earlier energy stories for Select Sector Spdr Tr (XLV): 3 cases
Select Sector Spdr Tr (XLV) the next day, across 3 earlier stories: average -1.92%, largest gain -1.92%, largest drop -1.92%, from 3 prices.
| Company | When | Average | Largest gain | Largest drop | Prices |
|---|---|---|---|---|---|
| Select Sector Spdr Tr (XLV) | the next day | -1.92% | -1.92% | -1.92% | 3 |
| Spdr Series Trust (XBI) | the next day | -3.49% | -3.49% | -3.49% | 1 |
| Johnson & Johnson (JNJ) | the next day | -2.54% | -2.54% | -2.54% | 2 |
How far Select Sector Spdr Tr (XLV) has moved since 18 Nov 2026
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | three days earlier | +2.60% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +0.58% | final price |
| Eli Lilly (LLY) | three days earlier | +2.06% | final price |
| Eli Lilly (LLY) | five days earlier | +1.56% | final price |
| MRK | three days earlier | +3.05% | final price |
| MRK | five days earlier | +2.66% | final price |
| Pfizer (PFE) | three days earlier | +1.55% | final price |
| Pfizer (PFE) | five days earlier | +3.48% | final price |
| Vertex Pharmaceuticals Inc / Ma (VRTX) | three days earlier | +0.84% | final price |
| Vertex Pharmaceuticals Inc / Ma (VRTX) | five days earlier | +2.45% | final price |
| Spdr Series Trust (XBI) | three days earlier | +3.62% | final price |
| Spdr Series Trust (XBI) | five days earlier | +7.54% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +1.95% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | +2.00% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Vertex Pharmaceuticals Inc / Ma (VRTX) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 75 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. David J. Taylor sold Vertex Pharmaceuticals Inc / Ma (VRTX), worth $1,001 - $15,000 on 26 Aug 2026. That is 84 days before publication. Filed 5 Sep 2026. View the filing.
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 15 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 29 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 75 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 42 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 49 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 75 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 89 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Companies in energy around Select Sector Spdr Tr (XLV)
Companies carried with this story
- XLV Select Sector Spdr Tr
In “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- XBI Spdr Series Trust
For “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 18 Nov 2026 story “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- VRTX Vertex Pharmaceuticals Inc / Ma
For “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Vertex Pharmaceuticals Inc / Ma (VRTX) is linked, with no stored direction, medium confidence. Reason on file: Vertex Pharmaceuticals (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- PFE Pfizer
In “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- LLY Eli Lilly
In “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
How energy news reaches Select Sector Spdr Tr (XLV)
On 18 Nov 2026, “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus” is the story that connects Select Sector Spdr Tr (XLV) to Energy.
What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
JNJ traded between 251.53 and 286.04 across 20 sessions. The latest close on file is 283.56.
The energy score for Select Sector Spdr Tr (XLV)
46 out of 100
“Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus” scores 46 out of 100. The score uses 1 source, and 6 linked companies.